ARPA-H, GEMMABio, and others receive $160 million to develop personalized gene therapy platforms
Strategic Public Funding and the THRIVE Program's Objectives
The Advanced Research Projects Agency for Health (ARPA-H) has decided to invest up to $160 million (approximately 210 billion KRW) over five years in the 'THRIVE' program for the treatment of rare genetic diseases. This funding aims to move beyond the traditional legacy approach of developing a single drug for a single disease, focusing instead on building a personalized precision medicine platform that responds in real-time to individual patient genetic variations. This strategic decision is seen as an effort to share the high risks of early-stage development, thereby opening up technological breakthroughs in the field of rare pediatric diseases, where private capital is often difficult to access. Beneficiary institutions are required to initiate the first human clinical trial (Phase 1) within three years and adopt an umbrella trial model that simultaneously treats patients with diverse variations, reflecting strict conditions.
CHOP's Expansion of Personalized CRISPR Platform and Clinical Roadmap
The Children's Hospital of Philadelphia (CHOP), which secured the largest funding of $38.9 million (approximately 51 billion KRW), gained global recognition last year for successfully treating a patient with carbamoylphosphate synthetase 1 deficiency (CPS1 deficiency), a rare metabolic disease, by administering the world's first N-of-1 personalized CRISPR therapy. CHOP's research team plans to use this funding to build a personalized gene therapy platform infrastructure targeting four rare genetic liver diseases, including homozygous familial hypercholesterolemia (HoFH), and to obtain clinical approval. This will be a significant milestone demonstrating that the technology for rapidly designing and delivering gene therapies via lipid nanoparticles (LNPs) for a single patient can evolve from a one-time miracle into a standardized medical platform.
GEMMABio and Profluent Bio Combine Forces to Innovate Base Editing with AI
James Wilson, a pioneer in gene therapy, who founded Gemma BioTherapeutics (GEMMABio), has partnered with Profluent Bio, a protein design artificial intelligence (AI) company, to conduct the 'RAPID' project. They are developing four modular base editing therapies that precisely correct single nucleotide variations in genes using AI models, and these will be delivered in the form of messenger ribonucleic acid (mRNA) in lipid nanoparticle (LNP) formulations. If this technology is successful, it is expected to significantly reduce manufacturing costs by automating and platformizing the existing manual gene therapy manufacturing process, and greatly improve access to treatment for rare genetic disease patients worldwide.
Expansion of Research into Various Rare Diseases and Ecosystem Creation
The THRIVE program also includes the Broad Institute-led consortium, which will receive up to $34.5 million to develop a gene editing platform for the treatment of pediatric rare epilepsy. Stanford University is targeting epidermolysis bullosa, a rare genetic skin disease that causes severe blistering, while St. Jude Children's Research Hospital and Massachusetts General Hospital are developing therapies for bone marrow failure and rare vascular diseases, respectively. This multifaceted research collaboration will undoubtedly serve as a major catalyst, bringing together academia and the biotech ecosystem to accelerate the commercialization of next-generation gene editing technologies.
ARPA-H's $160 million investment, by mandating Phase 1 entry within three years, is poised to accelerate the commercialization of personalized gene therapy platforms, currently stalled in the pre-clinical phase, at an unprecedented rate. The homozygous familial hypercholesterolemia (HoFH) market, projected to grow from $82.59 million in 2024 to $123.99 million in 2035, will see GEMMABio and Profluent Bio's AI-driven LNP base editing therapies emerge as a strong competitive pipeline against existing high-priced monoclonal antibody standard-of-care treatments like Regeneron's Evkeeza. Furthermore, in the epidermolysis bullosa (EB) field, with a global market size projected to reach up to $11.2 billion by the 2030s, Stanford University's platform research has the potential to reshape the future competitive landscape with Crystal BioTech's Vyjuvek, which already generates over $100 million in annual revenue. In the medium to long term, the public-funded, multi-patient umbrella trial model and AI-driven gene design standardization will revolutionize the high manufacturing costs and regulatory hurdles associated with ultra-expensive 'N-of-1' therapies, paving the way for a platform-centric business model for the entire gene therapy industry.
Source: FierceBiotech (rss)